

MICRUS ENDOVASCULAR CORP  
 Form 3/A  
 October 03, 2006

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â HENSON MICHAEL R		(Month/Day/Year)	MICRUS ENDOVASCULAR CORP [MEND]	
(Last)	(First)	(Middle)	06/15/2005	
821 FOX LANE			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	06/15/2005
SAN JOSE,Â CAÂ 95131			<input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input type="checkbox"/> Officer <input type="checkbox"/> Other	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			(give title below) (specify below)	<input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date			
		Title	Amount or Number of Shares		

Convertible Warrant <sup>(1)</sup>	Â <sup>(2)</sup>	01/01/2011	Common Stock	13,888 <sup>(3)</sup>	\$ <sup>(4)</sup>	I	JAIC-Henson MedFocus Fund II, LLC
Series B Preferred Stock	Â <sup>(2)</sup>	Â <sup>(5)</sup>	Common Stock	8,888	\$ <sup>(6)</sup>	I	Michael R. Henson, TTEE Henson Family Trust 1/8/87
Series D Preferred Stock	Â <sup>(2)</sup>	Â <sup>(5)</sup>	Common Stock	7,342 <sup>(7)</sup>	\$ <sup>(8)</sup>	D <sup>(7)</sup>	Â
Series E Preferred Stock	Â <sup>(2)</sup>	Â <sup>(5)</sup>	Common Stock	27,777 <sup>(9)</sup>	\$ <sup>(8)</sup>	I	JAIC-Henson MedFocus Fund, LLC
Series E Preferred Stock	Â <sup>(2)</sup>	Â <sup>(5)</sup>	Common Stock	27,777	\$ <sup>(8)</sup>	I	JAIC-Henson MedFocus Fund II, LLC

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HENSON MICHAEL R 821 FOX LANE SAN JOSE, CA 95131	Â X	Â	Â	Â

## Signatures

/s/ Michael R. Henson by Robert A Stern,  
Attorney-in-Fact.

10/03/2006

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Common Stock Warrant

(2) Immediately Exercisable

(3) This amount was erroneously reflected as 1,388 on the original Form 3.

(4) If the initial price to the public of the common stock sold is less than \$13.50 per share, these warrants become exercisable at \$0.000225 per share into an additional number of shares of common stock equal to 1,343,260 multiplied by the quotient of (i) \$13.50 less such initial price to the public, divided by (ii) such initial price to the public. If the initial price to the public of the common stock sold is greater than or equal to \$13.50 per share, the warrants are not exercisable into shares of common stock.

(5) Not Applicable.

(6) Each share of Series B Preferred stock converts into 1.3157894 shares. The original Form 3 reflected a 1.32 conversion rate.

(7) On the original Form 3, the ownership of 6,387 of these shares of Series D Preferred Stock was reflected as indirectly held by the Henson Family Trust, Michael Henson, Trustee but is held directly by Michael Henson. The remaining 958 shares were originally reflected as a Convertible Series D Preferred Warrant, but that warrant was exercised in April 2005 and should have been listed as Series D Preferred Stock.

Edgar Filing: MICRUS ENDOVASCULAR CORP - Form 3/A

(8) Converts on a 1 to 1 basis.

(9) On the original Form 3, Column 3 reflected 55,555 shares of Series E Preferred Stock as indirectly held by the JAIC-Henson MedFocus Fund, LLC. This number was incorrect as 27,777 of these shares were indirectly held by the JAIC-Henson MedFocus Fund II, LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.